<a href="https://laohu8.com/S/SMHGF">Simcere Pharmaceutical</a> Group Ltd. Reports 15.1% Rise in Revenue to RMB3,585 Million for H1 2025; Innovative Pharmaceutical Business Revenue Up 26%
Simcere Pharmaceutical Group Ltd. reported its unaudited financial results for the six months ended June 30, 2025. The Group recorded revenue of RMB3,585 million, an increase of 15.1% compared to RMB3,114 million for the same period in 2024. Revenue from the innovative pharmaceutical business reached RMB2,776 million, accounting for 77.4% of total revenue and representing a 26.0% increase from RMB2,203 million in the prior-year period. Profit attributable to equity shareholders of the Company was RMB604 million, a rise of RMB147 million or 32.2% from RMB457 million a year earlier. Adjusted profit attributable to equity shareholders stood at RMB651 million, up RMB113 million or 21.1% from RMB538 million in the corresponding period of 2024. Simcere Pharmaceutical Group stated that it continues to focus on R&D-driven innovation, with business operations primarily targeting neuroscience, oncology, autoimmune, and anti-infection therapeutic areas. No specific outlook or guidance for future periods was included in the released report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.